ERBB2 and gastric cancer: Promising progress has been made with dual paratope ADCs in advanced gastric cancer (NCT03821233), and ZW49, capable of targeting both HER2 and ZW25, has shown efficacy and low resistance in patients who have not responded to standard treatment with T-DM1.